Non-Hodgkin Lymphoma News

• CCC 2020Lymphoma Risk Low After TNF Inhibitor Treatments Tumor necrosis factor (TNF) inhibitors are among the most effective treatments for inflammatory bowel disease, but questions about cancer risk have kept some clinicians from prescribing them.
  Medscape Medical News, January 24, 2020
• No Support for Lymphoma Risk With Anti-TNF Therapy for Pediatric IBD A new study finds no support for an increased risk of lymphoma in children with inflammatory bowel disease (IBD) treated with anti-tumor necrosis factor (TNF) agents.
  Reuters Health Information, January 23, 2020
• Drug Developers Take Fresh Aim at 'Guided-Missile' Cancer Drugs Dozens of drugmakers are conducting human trials for a record 89 therapies that pair antibodies with toxic agents to fight cancer, evidence of renewed confidence in an approach that has long fallen short of its promise, an analysis compiled for Reuters shows.
  Reuters Health Information, January 06, 2020
• A Mixed Start for Immunotherapy in Childhood Cancers KEYNOTE-051 establishes a recommended pediatric dose for pembrolizumab and shows encouraging antitumor activity in one cancer type, but it was less effective in multiple other malignancies.
  Medscape Medical News, January 02, 2020
• Regular Exercise Linked to Reduced Risk of Several Cancers Engaging in moderate-intensity activity several times a week appears to reduce the risk of several different cancer types, with hints of a dose-response relationship.
  Medscape Medical News, December 31, 2019
• ASH 2019In Follicular Lymphoma, Can MRD Predict Relapse or Define Cure? In a first-of-its-kind study, patients with follicular lymphoma who were in remission were followed for minimal residual disease (MRD) status, which may guide treatment.
  Medscape Medical News, December 09, 2019
• ASH 2019Study Halted; 'Hyperprogression' Seen With Nivolumab for R/R PTCL A phase 2 study suggests the checkpoint inhibitor is not the hoped-for salvage treatment in relapsed or refractory peripheral T-cell lymphoma.
  Medscape Medical News, December 09, 2019
• ASH 2019Allogeneic Transplant Best in Follicular Lymphoma, but Worth It? Long-term data show better overall survival after an allogeneic transplant for relapsed follicular lymphoma than with autologous transplant, but an expert wonders about recommending transplant at all.
  Medscape Medical News, December 08, 2019
• ASH 2019Some Patients with DLBCL Can Skip Radiation: 'It's a Win' A 'no radiation' approach may be possible for managing non-bulky (stage I/II) disease in patients with DLBCL. These patients may do well with just 4 cycles of R-CHOP after an interim PET-negative scan.
  Medscape Medical News, December 08, 2019
• ASH 2019An Off-the-Shelf Drug to Rival CAR T Cells: 'Very Exciting' A novel bispecific antibody, mosunetuzumab, has shown complete remissions in patients with poor prognosis non-Hodgkin's lymphoma, even those previously treated with CAR T cells.
  Medscape Medical News, December 07, 2019
• ASH 2019'Real-World' Data Show CAR-T Therapies Are Cost Effective CAR-T cell therapy comes with a formidable sticker price, but a new study showed that it can actually reduce healthcare expenditures in the long term.
  Medscape Medical News, December 07, 2019
• ASH 2019The Next 'Big Thing' for Blood Cancers Featured at ASH 2019 CAR T cells have been center stage at the American Society of Hematology meeting for the last few years, but new technologies are coming that may encroach on their use.
  Medscape Medical News, December 07, 2019
• Novartis's $90 Mln Swiss Factory to Help Solve Cell Therapy Bottleneck Swiss drugmaker Novartis's new $90 million cell and gene therapy factory in northern Switzerland is on track to begin commercial production of treatments, including Kymriah for cancer and Zolgensma for spinal muscular atrophy, in 2020.
  Reuters Health Information, November 28, 2019
• Patients With Cancer at Increased Risk for Cardiovascular Death A population-based study found that cancer patients are at increased risk for death from cardiovascular disease compared to general population, highlighting the importance of cardio-oncology as a subspecialty.
  Medscape Medical News, November 26, 2019
• Morphosys to Boost Size of Tafasitamab Drug Trial on Encouraging Interim Data German biotech company Morphosys said more patients would be recruited for a study testing its most advanced drug against a common type of blood cancer, following an encouraging interim data readout.
  Reuters Health Information, November 18, 2019
• After Backlash, Teva Will Resume Production of Vincristine Only a few months after announcing that it will cease production of this essential medicine for childhood cancers, Teva has announced it will jump back into the market.
  Medscape Medical News, November 18, 2019
• 'Real Crisis': Ruinous Out-of-Pocket Costs for Blood Cancers The cost of blood cancer care is so high that many Medicare patients do not start treatment in a timely way, and some fail to start treatment at all.
  Medscape Medical News, November 05, 2019
• Newly Diagnosed Hodgkin Lymphoma Can Be Safely Managed During Pregnancy Hodgkin lymphoma diagnosed during pregnancy can be safely managed without interruption of pregnancy in most cases, according to new findings.
  Reuters Health Information, October 18, 2019
• Novel Combination Strategy Active in Poor-Risk AML An induction cycle of decitabine followed by twice-weekly selinexor has significant activity in poor-risk AML but is a challenging regimen in elderly patients.
  Medscape Medical News, October 17, 2019
• Second Primaries Different in Early- vs Late-Stage DLBCL Different biologies of early- vs late-stage diffuse large B-cell lymphoma may drive a different pattern and timing of secondary primary malignancies.
  Medscape Medical News, October 14, 2019